Literature DB >> 8547097

Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels.

K Fijnvandraat1, M Peters, J W ten Cate.   

Abstract

In an attempt to explain the substantial inter-individual variability in half-life of infused factor VIII (FVIII) among haemophilia A patients, we studied the correlation of pre-infusion von Willebrand factor antigen (vWFAg) levels and the half-life of a recombinant-DNA-derived FVIII (r-VIII SQ. Pharmacia, Sweden). Intra-individual variation in half-life was small (range of variation 0-2.1 h) in 12 severely affected haemophiliacs who received two doses of FVIII concentrate. In contrast, inter-individual variation in half-life was large (range of half-lives 6-28.8 h). A strong correlation between half-life and pre-infusion vWFAg levels was present (r = 0.87, P = 0.0003). We conclude that the half-life of infused recombinant FVIII is related to pre-infusion vWFAg levels in severely affected haemophilia A patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8547097     DOI: 10.1111/j.1365-2141.1995.tb05325.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.

Authors:  Hendrika Hazendonk; Karin Fijnvandraat; Janske Lock; Mariëtte Driessens; Felix van der Meer; Karina Meijer; Marieke Kruip; Britta Laros-van Gorkom; Marjolein Peters; Saskia de Wildt; Frank Leebeek; Marjon Cnossen; Ron Mathôt
Journal:  Haematologica       Date:  2016-07-06       Impact factor: 9.941

Review 2.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Up-regulation of platelet activation in hemophilia A.

Authors:  Esther R van Bladel; Mark Roest; Philip G de Groot; Roger E G Schutgens
Journal:  Haematologica       Date:  2011-03-21       Impact factor: 9.941

4.  Progress of in vitro factor VIII coagulant activity from 0 to 8 hours after reconstitution.

Authors:  Ye Jee Shim; Kun Soo Lee; Uk Hyun Kim; Jin Kyung Suh; Sae Yun Baik; Shin Young Hyun
Journal:  Blood Res       Date:  2014-12-23

5.  Applicability of the Thrombin Generation Test to Evaluate the Hemostatic Status of Hemophilia A Patients in Daily Clinical Practice.

Authors:  Ángel Bernardo; Alberto Caro; Daniel Martínez-Carballeira; José Ramón Corte; Sonia Vázquez; Carmen Palomo-Antequera; Alfredo Andreu; Álvaro Fernández-Pardo; Julia Oto; Laura Gutiérrez; Inmaculada Soto; Pilar Medina
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

6.  Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.

Authors:  E Berntorp; B Fuchs; M Makris; R Montgomery; V Flood; J S O'Donnell; A B Federici; D Lillicrap; P James; U Budde; M Morfini; P Petrini; S Austin; C Kannicht; V Jiménez-Yuste; C Lee
Journal:  Haemophilia       Date:  2013-03       Impact factor: 4.287

7.  Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.

Authors:  Barbara A Konkle; Oleksandra Stasyshyn; Pratima Chowdary; David H Bevan; Tim Mant; Midori Shima; Werner Engl; Jacqueline Dyck-Jones; Monika Fuerlinger; Lisa Patrone; Bruce Ewenstein; Brigitt Abbuehl
Journal:  Blood       Date:  2015-07-08       Impact factor: 22.113

8.  Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.

Authors:  Sven Björkman; Anna Folkesson; Siv Jönsson
Journal:  Eur J Clin Pharmacol       Date:  2009-06-26       Impact factor: 2.953

9.  Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes.

Authors:  Beth Boulden Warren; Linda Jacobson; Christine Kempton; George R Buchanan; Michael Recht; Deborah Brown; Cindy Leissinger; Amy D Shapiro; Thomas C Abshire; Marilyn J Manco-Johnson
Journal:  Haemophilia       Date:  2019-05-21       Impact factor: 4.263

10.  Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients.

Authors:  Kathelijn Fischer; Ronan Pendu; Carina J van Schooten; Karin van Dijk; Cécile V Denis; H Marijke van den Berg; Peter J Lenting
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.